hepatocellular%20carcinoma
HEPATOCELLULAR CARCINOMA

Hepatocellular carcinoma is malignancy that originates from the liver.

Physical signs are hepatomegaly and ascites. It is usually asymptomatic for much of its natural history.

Liver cancer is the second most common cause of cancer-related mortality worldwide & hepatocellular carcinoma accounts for >90% of liver cancers.

 

Hepatocellular%20carcinoma Management

Surveillance

  • Multiphasic cross-sectional imaging (eg CT or MRI) is the preferred method for surveillance following treatment due to its reliability in assessing arterial vascularity that is associated with increased risk of hepatocellular carcinoma recurrence following treatment
    • Test should be done every 3-6 months for 2 years, then every 6-12 months 
  • Serum alpha-fetoprotein (AFP) levels are associated with poor prognosis following treatment and should be measured every 3-6 months for 2 years, then every 6-12 months
  • In the event of disease recurrence, re-evaluation according to the initial work-up should be considered
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 18 Nov 2020
The distribution of body fat contributes to the risk of coronary heart disease (CHD), with the risk of cardiovascular events further increasing among individuals with low liver fat (LF) and high visceral adipose tissue (VAT) or abdominal fat, results of a recent study have shown.
Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).